Home / World Marketplace / Archive by category Global Health & Biotech (Page 22)

Archive by category Global Health & Biotech

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

TEL AVIV, Israel, June 03, 2025 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% [...]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio Builds on established experience and leadership in oncology and immunology [...]

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research [...]

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-’749 (olanzapine) to Date

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-’749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva [...]

EU Good Food Officially Launches in Korea

European culinary excellence arrives in Korea, embracing modern lifestyles and sustainable values SEOUL, South Korea, May 30, 2025 (Korea Bizwire) — The “EU Good Food – Good Life” campaign, funded by the European Union, was officially launched in South Korea, marking the start of its public communication activities in the country. This three-year initiative (2024–2027), co-funded [...]

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, [...]

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potential Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (Korea [...]

Ascom launches share buyback program

Ad hoc announcement pursuant to Art. 53 LR Baar, Switzerland, May 28, 2025 Ascom Holding AG will start its previously announced share buyback program on 30 May 2025. Ascom mandated Zürcher Kantonalbank to repurchase up to a maximum of 3 million registered shares on the second trading line on SIX Swiss Exchange and up to [...]

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease Candidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populations TEL AVIV, Israel, May 27, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries, Ltd. [...]

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

TEL AVIV, Israel, May 27, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming investor conferences in June as follows: Jefferies Global Healthcare Conference Chris Fox, EVP U.S. Commercial and Dr. Eric Hughes, EVP Global R&D and Chief Medical [...]